Real-World Experience with Nivolumab in Metastatic Renal Cell Carcinoma Patients Who Have Progressed on Prior Therapies: A Single-Center Study from India

Real-World Experience with Nivolumab in Metastatic Renal Cell Carcinoma Patients Who Have Progressed on Prior Therapies: A Single-Center Study from India

Abstract Amit Rauthan Introduction Nivolumab monotherapy is approved for the treatment of metastatic renal cell carcinoma (mRCC) patients who have progressed on prior therapies based on the pivotal Ch...

Full description

Bibliographic Details
Main Authors:	Amit Rauthan, Nitin Yashas Murthy, Poonam Patil, Gaurav Nigade, SP Somashekhar, Shabber S. Zaveri
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2022-04-01
Series:	South Asian Journal of Cancer
Subjects:	nivolumab metastatic rcc iraes immunotherapy indian experience
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1740373

Similar Items

Longer Control of Nivolumab in Metastatic Renal Cell Carcinoma Patients with End-Stage Kidney Disease on Dialysis
by: Ryota Morinaga, et al.
Published: (2019-08-01)

Bullous pemphigoid in a metastatic lung cancer patient associated with nivolumab
by: Yuka Maya, MD, et al.
Published: (2020-12-01)

Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab
by: Soichi Matsumura, et al.
Published: (2023-06-01)

Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience
by: Ananya Pareek, et al.
Published: (2022-01-01)

Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series
by: Luigi Liguori, et al.
Published: (2023-11-01)

Delayed nivolumab‐induced hepatotoxicity during pazopanib treatment for metastatic renal cell carcinoma: An autopsy case
by: Maki Todo, et al.
Published: (2019-09-01)

Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer
by: Hirofumi Ohmura, et al.
Published: (2023-10-01)

Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report
by: Chikako Shibata, et al.
Published: (2019-06-01)

Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses
by: Thomas K. Le, et al.
Published: (2022-04-01)

Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
by: Joanna Bialek, et al.
Published: (2022-12-01)

USE OF IMMUNOTHERAPY IN THE TREATMENT OF A PATIENT WITH TWO SIMULTANEOUS METASTATIC DISEASES
by: Matej Penava, et al.
Published: (2023-01-01)

Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases)
by: L. Yu. Vladimirova, et al.
Published: (2021-08-01)

Remarkable antitumor effect of nivolumab in a patient with metastatic renal cell carcinoma previously treated with a peptide‐based vaccine
by: Ryoma Kurahashi, et al.
Published: (2020-03-01)

Long-term response with the atypical reaction to nivolumab in microsatellite stability metastatic colorectal cancer: A case report
by: Nataliya Babyshkina, et al.
Published: (2024-01-01)

Surgical treatment of metastatic brain tumor from gastric cancer during therapy with nivolumab: A case report
by: Yoshiyasu Matsumoto, et al.
Published: (2022-06-01)

Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study
by: Umberto Basso, et al.
Published: (2022-05-01)

Stage 4 Cytokine Release Syndrome Caused by the First Dose of Nivolumab and Ipilimumab Combination Therapy in a Patient with Metastatic Melanoma Successfully Treated with Methylprednisolone, Tocilizumab, and Etanercept
by: Sasmith R. Menakuru, et al.
Published: (2022-06-01)

Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
by: Sadanori Furudate, et al.
Published: (2016-10-01)

Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough
by: Veronica Mollica, et al.
Published: (2021-07-01)

Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer
by: Yukinori Ozaki, et al.
Published: (2022-12-01)

Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report
by: Elisa Gozzi, et al.
Published: (2020-05-01)

Combination treatment with nivolumab and Rigvir of a progressive stage IIC skin melanoma patient
by: Linda Brokāne, et al.
Published: (2019-06-01)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
by: Asim Amin, et al.
Published: (2018-10-01)

Case Report: Metastatic renal cell carcinoma to the thyroid— A rare encounter
by: Megan Shepherd, et al.
Published: (2022-11-01)

Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
by: Koji Iinuma, et al.
Published: (2021-04-01)

Complete response of metastatic renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus ipilimumab
by: Michikata Hayashida, et al.
Published: (2022-07-01)

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial
by: Maartje W. Rohaan, et al.
Published: (2022-08-01)

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
by: Takashi Kawahara, et al.
Published: (2019-07-01)

Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab
by: Johanna Noel, et al.
Published: (2022-06-01)

Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient
by: Vincent Pillonel, et al.
Published: (2019-12-01)

Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient
by: George Samonis, et al.
Published: (2022-11-01)

Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab
by: Brett A. Schroeder, et al.
Published: (2020-01-01)

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 studyResearch in context
by: Marwan Fakih, et al.
Published: (2023-04-01)

Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
by: James Luke Godwin, et al.
Published: (2017-05-01)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
by: Kazuyuki Numakura, et al.
Published: (2021-09-01)

First-line treatment of metastatic melanoma: role of nivolumab
by: Force J, et al.
Published: (2017-02-01)

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
by: Domenico Mallardo, et al.
Published: (2023-10-01)

Complete response of metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus cabozantinib
by: Michikata Hayashida, et al.
Published: (2023-11-01)

Autoimmune hemolytic anemia during long‐term administration of nivolumab for metastatic melanoma
by: Koji Nakajima, et al.
Published: (2021-10-01)

Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
by: Mariaelena Capone, et al.
Published: (2020-03-01)